Literature DB >> 1380673

Processing of mutant cystic fibrosis transmembrane conductance regulator is temperature-sensitive.

G M Denning1, M P Anderson, J F Amara, J Marshall, A E Smith, M J Welsh.   

Abstract

Cystic fibrosis transmembrane conductance regulator (CFTR) is a plasma membrane Cl- channel regulated by cyclic AMP-dependent phosphorylation and by intracellular ATP. Mutations in CFTR cause cystic fibrosis partly through loss of cAMP-regulated Cl- permeability from the plasma membrane of affected epithelia. The most common mutation in cystic fibrosis is deletion of phenylalanine at residue 508 (CFTR delta F508) (ref. 10). Studies on the biosynthesis and localization of CFTR delta F508 indicate that the mutant protein is not processed correctly and, as a result, is not delivered to the plasma membrane. These conclusions are consistent with earlier functional studies which failed to detect cAMP-stimulated Cl- channels in cells expressing CFTR delta F508 (refs 16, 17). Chloride channel activity was detected, however, when CFTR delta F508 was expressed in Xenopus oocytes, Vero cells and Sf9 insect cells. Because oocytes and Sf9 cells are typically maintained at lower temperatures than mammalian cells, and because processing of nascent proteins can be sensitive to temperature, we tested the effect of temperature on the processing of CFTR delta F508. Here we show that the processing of CFTR delta F508 reverts towards that of wild-type as the incubation temperature is reduced. When the processing defect is corrected, cAMP-regulated Cl- channels appear in the plasma membrane. These results reconcile previous contradictory observations and suggest that the mutant most commonly associated with cystic fibrosis is temperature-sensitive.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1380673     DOI: 10.1038/358761a0

Source DB:  PubMed          Journal:  Nature        ISSN: 0028-0836            Impact factor:   49.962


  440 in total

Review 1.  The pathogenic consequences of a single mutated CFTR gene.

Authors:  U Griesenbach; D M Geddes; E W Alton
Journal:  Thorax       Date:  1999-08       Impact factor: 9.139

Review 2.  Antagonists to the rescue.

Authors:  W J Welch; M Howard
Journal:  J Clin Invest       Date:  2000-04       Impact factor: 14.808

Review 3.  Novel pharmacologic therapies for cystic fibrosis.

Authors:  P L Zeitlin
Journal:  J Clin Invest       Date:  1999-02       Impact factor: 14.808

Review 4.  Defective folding and rapid degradation of mutant proteins is a common disease mechanism in genetic disorders.

Authors:  N Gregersen; P Bross; M M Jørgensen; T J Corydon; B S Andresen
Journal:  J Inherit Metab Dis       Date:  2000-07       Impact factor: 4.982

5.  Stable, polarised, functional expression of Kir1.1b channel protein in Madin-Darby canine kidney cell line.

Authors:  B Ortega; I D Millar; A H Beesley; L Robson; S J White
Journal:  J Physiol       Date:  2000-10-01       Impact factor: 5.182

Review 6.  Cystic fibrosis as a disease of misprocessing of the cystic fibrosis transmembrane conductance regulator glycoprotein.

Authors:  J R Riordan
Journal:  Am J Hum Genet       Date:  1999-06       Impact factor: 11.025

Review 7.  Rescuing protein conformation: prospects for pharmacological therapy in cystic fibrosis.

Authors:  Marina S Gelman; Ron R Kopito
Journal:  J Clin Invest       Date:  2002-12       Impact factor: 14.808

8.  Adenosine A2A receptor is involved in cell surface expression of A2B receptor.

Authors:  Kengo Moriyama; Michail V Sitkovsky
Journal:  J Biol Chem       Date:  2010-10-06       Impact factor: 5.157

9.  A posttranslational modification code for CFTR maturation is altered in cystic fibrosis.

Authors:  Sandra Pankow; Casimir Bamberger; John R Yates
Journal:  Sci Signal       Date:  2019-01-01       Impact factor: 8.192

10.  Bestrophin expression and function in the human pancreatic duct cell line, CFPAC-1.

Authors:  Laura L Marsey; John P Winpenny
Journal:  J Physiol       Date:  2009-02-23       Impact factor: 5.182

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.